Sweden's Alligator Bioscience Q3 sales fall as R&D winds down

Alligator Bioscience AB

Today 07:13

Overview
Sweden biotech firm reported Q3 net sales fell sharply as it wound down internal R&D
Company completed SEK 58.8 mln rights issue to fund wind-down and repaid bridge loans
Internal drug development discontinued; focus now on financial interest in HLX22 program

Outlook
Company did not provide specific financial guidance for upcoming quarters or full year in its press release
First royalty revenues from HLX22 expected around 2030
Reduced cost base expected to be fully in effect from Q2 2027

Result Drivers
STRATEGIC SHIFT - Co discontinued internal drug development and refocused on financial interest in HLX22
COST REDUCTION - Wind-down of internal operations and reduced cost base expected to be fully in effect from Q2 2027
CAPITAL INFLOW - SEK 58.8 mln raised from rights issue used to fund wind-down and repay bridge loans

Company press release: ID:nMFN7lYThJ

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
 
SEK 200,000
 
Q3 Adjusted Loss Per Share
 
SEK 0.03
 
Q3 Net Loss
 
SEK 16.70 mln
 
Q3 EBIT
 
-SEK 19.30 mln
 

Analyst Coverage
Wall Street's median 12-month price target for Alligator Bioscience AB is SEK0.04, about 252.2% above its October 21 closing price of SEK0.01

Reuters Recommended Reads
Oct 22 - Sweden's Orexo Q3 revenue falls sharply, net loss widens
Oct 22 - Netherlands' Argenx Q3 sales jump on strong VYVGART demand 
Oct 19 - HK-listed Metis TechBio, Eli Lilly strike drug-delivery deal worth up to $1.1 billion

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)